NCT01451515View on ClinicalTrials.gov

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 25, 2012

Primary Completion Date

May 8, 2021

Study Completion Date

May 31, 2022

Conditions
Lymphoblastic Lymphoma
Interventions
DRUG

Prednisone

Given orally (PO).

DRUG

Vincristine

Given intravenously (IV).

DRUG

Daunorubicin

Given IV.

DRUG

PEG-asparaginase

Given intramuscularly (IM) or IV.

DRUG

Erwinia asparaginase

Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.

DRUG

Doxorubicin

Given IV.

DRUG

Cyclophosphamide

Given IV.

DRUG

Cytarabine

Given IV or IT.

DRUG

Thioguanine

Given PO.

DRUG

Clofarabine

Given IV.

DRUG

Methotrexate

Given IV, IM or IT.

DRUG

Mercaptopurine

Given PO.

DRUG

Dexamethasone

Given PO or IV.

DRUG

Hydrocortisone

Given IT.

DRUG

Etoposide

Given IV.

Trial Locations (2)

38105

St. Jude Children's Research Hospital, Memphis

92123

Rady Children's Hospital San Diego, San Diego

All Listed Sponsors
collaborator

National University of Singapore

OTHER

lead

St. Jude Children's Research Hospital

OTHER

NCT01451515 - NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | Biotech Hunter | Biotech Hunter